Table 2.

ACE-inhibitors, b-blockers, Ca-antagonists, and sartans utilization in reference DDD/1000 inh/dayduring 2016–2019

INN	2016	2017	2018	2019		2016	2017	2018	2019
ACE inhibitors					AT -receptor blockers
Enalapril	17.008	18.102	15.722	12.124	Losartan	0.504	3.551	3.157	2.901
Lisinopril	12.078	13.567	12.036	11.103	Eprosartan	0.019	0.129	0.185	0.173
Perindopril	4.253	4.557	3.994	4.250	Valsartan	13.996	19.807	16.214	10.565
Ramipril	19.249	21.770	20.896	19.613	Irbesartan	2.587	4.237	4.798	4.212
Quinapril	0.380	0.391	0.326	0.164	Candesartan	2.626	5.405	6.134	7.072
Fosinopril	1.150	1.280	0.838	1.039	Telmisartan	9.408	11.310	10.271	7.373
Trandolapril	0.528	0.506	0.300	0.731	Olmesartan	0.683	5.643	3.750	2.389
Zofenopril	1.266	1.980	2.028	1.779	Total	29.823	50.082	44.509	34.685
Total	55.912	62.153	56.140	50.803	Ca-antagonists
Β- blockers					Amlodipine	23.016	24.545	22.930	20.495
Metoprolol	7.092	7.342	7.062	6.553	Felodipine	3.591	3.266	2.665	2.286
Atenolol	0.809	0.744	0.347	0.363	Nifedipine	3.106	2.846	2.627	2.439
Bisoprolol	29.263	23.380	25.228	23.895	Nimodipine	0.003	0.002	0.002	0.002
Nebivolol	14.752	19.473	16.926	15.491	Lacidipine	1.564	1.625	1.565	1.453
Carvedilol	2.372	2.281	2.025	1.835	Lercanidipine	16.018	25.747	16.694	20.710
Total	54.288	53.22	51.588	48.137	Total	47.298	58.031	46.483	47.385